NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities

NCT02915224

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Chronic Lymphocytic Leukemia

Interventions: Chlorambucil, Obinutuzumab

Countries: Greece

This multicenter, single arm, non-interventional, observational study will evaluate the efficacy and safety of obinutuzumab in daily clinical practice in participants with chronic lymphocytic leukemia (CLL). The study will also assess cost of disease management. The total length of the study is 42 months.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Participants with untreated CLL and comorbidities, for which the physician has already decided to use obinutuzumab in association with chlorambucil

Exclusion Criteria:

* Participation in another clinical trial during the study

Locations (11)

Alexandroup, Greece
Athens, Greece
Athens, Greece
Athens, Greece
Athens, Greece
Heraklion, Greece
Larissa, Greece
Pátrai, Greece
Piraeus, Greece
Thessaloniki, Greece
Thessaloniki, Greece